	US 11,858,977 B2
	Modified TCR and uses thereof
Chengfei Pu, Shanghai (CN); Dongqi Chen, Shanghai (CN); and Xiaogang Shen, Shanghai (CN)
Assigned to Innovative Cellular Therapeutics Holdings, Ltd., George Town (KY); and Innovative Cellular Therapeutics, Inc., Rockville, MD (US)
Filed by Innovative Cellular Therapeutics Holdings, Ltd., Grand Cayman (KY); and Innovative Cellular Therapeutics, Inc., Rockville, MD (US)
Filed on Oct. 22, 2020, as Appl. No. 17/077,451.
Claims priority of provisional application 62/929,529, filed on Nov. 1, 2019.
Claims priority of provisional application 62/925,462, filed on Oct. 24, 2019.
Prior Publication US 2021/0122802 A1, Apr. 29, 2021
Int. Cl. C07K 14/725 (2006.01); C07K 14/705 (2006.01)

CPC C07K 14/7051 (2013.01) [C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)]

18 Claims

1. A polynucleotide comprising a sequence encoding a ζ-chain of TCR-CD3 complex linked to one or more co-stimulatory signaling domains, wherein the polynucleotide comprises a sequence encoding amino acid sequence SEQ ID NO: 18 or SEQ ID NO: 19.